Protocol Ledger

NCT04064060 · Phase III · RECRUITING

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Interventional Phase III clinical trial protocol NCT04064060 sponsored by Bristol Myers Squibb in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-12 Enrollment: 665 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04064060
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)665 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04064060
Protocol FieldVerified Registry Value
NCT IdentifierNCT04064060
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment665 participants (ESTIMATED)
Registered Start Date2019-08-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04064060
Hospital Research SiteLocationSite Profile
Vanderbilt University Medical CenterNashville, TNOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI